Singapore eDevelopment Limited
(Company Registration Number 200916763W)
7 *Temasek* Boulevard, #29-01B
Suntec Tower One, Singapore 038987

HWH World Pte. Ltd. Signs Binding Term Sheet with Todos Medical Ltd for Exclusive Marketing Rights Over Two Breast Cancer Screening Tests

SINGAPORE, 16 September 2019 – Singapore Exchange-listed Singapore eDevelopment Limited (Stock Code 40V) ("**SeD**") wishes to announce that its wholly-owned Singapore incorporated subsidiary, HWH World Pte. Ltd. ("**HWH World**"), has entered into a binding term sheet with Todos Medical Ltd (OTCQB: TOMDF) ("**Todos Medical**") in relation to the grant of exclusive marketing rights by Todos Medical to HWH World for Todos Medical's TM-B1 and TM-B2 breast cancer screening tests.

The collaboration enables Todos Medical to leverage on, and market its breast cancer screening tests, to HWH World's network of members based in Singapore, Malaysia, the Philippines, Vietnam, Thailand, Indonesia, South Korea, Hong Kong, China - Mainland China and Taiwan, Africa, Australia, Latin America, Canada and the United States of America; excluding physicians and hospitals, and excluding consumers who are not members of HWH World's network of members.

Todos Medical is an Israeli in-vitro diagnostic company engaged in the development of blood tests for the early detection of a variety of cancers. Todos Medical has developed the TM-B1 and TM-B2 breast cancer screening tests using Todos Biomedical Infrared Analyses ("**TBIA**"), a proprietary patented method for cancer screening that makes use of peripheral blood smear analysis and incorporates other disciplines such as biochemistry, physics and signal processing. TBIA is also based on the effect cancer has on the immune system which triggers biochemical changes in peripheral blood mononuclear cells and plasma.

Both the TM-B1 and TM-B2 breast cancer screening tests have received the CE mark, a certification mark that indicates conformity with health, safety and environmental protection standards for products sold within the European Economic Area.

"*Todos Medical's innovative artificial intelligence-based blood testing technology has shown strong results for breast cancer screening and diagnosis in Singapore,*" said Mr Chan Heng Fai, Executive Chairman of SeD and Chairman of HWH World. "*This represents a tremendous opportunity for HWH World's network of members to take control of their healthcare by getting better information about potential cancer to ensure they are seeking treatment early in the disease progression. This will improve the well-being of our female members and help differentiate us from other wellness programs in the market.*

Many Asian women are forced to have unnecessary breast biopsies because mammograms are not very effective in the Asian population. Todos Medical has identified a solution to this problem, and HWH World is looking forward to bringing the TM-B1 and TM-B2 breast cancer screening tests to our members in Asia and as we expand into North America."

"*Having just completed a substantial clinical study in Singapore that demonstrated the superiority of our assay versus mammography in prospectively classifying cancer and non-cancer subjects, especially among those with inconclusive mammogram results (BI-RADS III/IV), we are pleased to secure our first Asian partner in HWH World. Our two companies are aligned in viewing the significant value in mitigating the need for expensive and invasive biopsies by utilizing a blood test that will determine whether a biopsy is necessary,*" said Herman Weiss, M.D., President and Chief Executive Officer of Todos Medical.

Todos Medical and HWH World have agreed that Singapore will be the first jurisdiction in which they will partner to launch the operations.

Shareholders and potential investors of SeD are advised to exercise caution when dealing or trading in the securities of SeD. Shareholders and potential investors of SeD are advised to read this Media Release and any further announcements made by SeD carefully. Shareholders and potential investors of SeD should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions they should take.

End of Media Release

About Singapore eDevelopment Limited

Incorporated on 9 September 2009 and listed on the Singapore Exchange in July 2010, Singapore eDevelopment Limited is primarily involved in (i) property development and investments primarily in the United States and Western Australia; (ii) information technology-related businesses; (iii) development, research, testing, manufacturing, licensing and distribution of biomedical products; and (iv) investment activities.

For more information, please visit: www.SeD.com.sg or email contact@sed.com.sg.

About HWH World Pte. Ltd.

HWH World Pte. Ltd. is a wholly-owned indirect subsidiary of Singapore eDevelopment Limited primarily involved in direct sales/network marketing of health and wellness products and services.

This Media Release have been reviewed by the Company's Sponsor, Hong Leong Finance Limited. It has not been examined or approved by the Exchange and the Exchange assumes no responsibility for the contents of this Media Release, including the correctness of any of the statements or opinions made or reports contained in this Media Release.

The contact person for the Sponsor is Mr Tang Yeng Yuen, Vice President, Head of Corporate Finance, Hong Leong Finance Limited, at 16 Raffles Quay, #01-05 Hong Leong Building, Singapore 048581, telephone: +65 6415 9886.